Antibody-drug Conjugates

Specificity Stability Potency

We are at the leading edge of antibody-drug conjugate (ADC) research and their use in the treatment of cancer. ADCs harness the targeting ability of antibodies to deliver cell-killing agents directly to cancer cells. This innovative approach to therapy offers meaningful efficacy while minimizing side effects.

 

Antibody-drug conjugate (ADC) technology

Our antibody-drug conjugate (ADC) technology combines the specificity of monoclonal antibodies, innovative linker systems, and the power of potent cell-killing agents to treat cancer. Using our proprietary industry-leading technology, we are able to optimize each ADC to potentially improve outcomes for patients.

Monoclonal Antibody
  • Unlike traditional chemotherapy which may be nonspecific, antibodies specifically target tumor-associated proteins, such as those found on the surface of tumor cellsa
  • Ideal antibodies recognize and bind tightly to the target cell, have minimal binding to healthy cells, and have prolonged systemic exposureb,c
  • At Seattle Genetics, we apply our knowledge of disease biology to screen for and engineer antibodies with ideal properties to serve as the foundation of our ADCs 

a  Ducry L et al. Bioconjug Chem. 21(1):5-13; 2010
b  Carter P et al. Am Assoc Cancer Res Educ Book. 2005(1):147-154; 2005 
c  Peters and Brown. Biosci Rep. 35(4); 2015

Linker
  • The linker chemically attaches the cell-killing (cytotoxic) agent to the antibodya
  • Ideal linkers are stable in systemic circulation but release the cytotoxic payload once inside target cells thereby limiting off-target toxicitya
  • At Seattle Genetics, we are continually developing new classes of linkers to specifically deliver the maximum cell-killing dose to the target cell, increasing antitumor activity while potentially limiting side effects for patients 

a  Diamantis and Banerji. Br J Cancer. 114(4): 362-367; 2016

Cytotoxic Payload
  • The cytotoxic agent kills the targeted tumor cell upon internalization and release from the ADCa
  • Ideal cytotoxic agents remain stable while linked to the ADC, are highly potent against the specific tumor type, maintain activity in multidrug-resistant tumor cells, and induce cell deatha
  • At Seattle Genetics, in addition to our proven cytotoxic agents, auristatins (microtubule disrupting agent), we continue to develop new cytotoxic agents that have increased potency, overcome drug resistance, and have novel mechanisms of action

a Drachman and Senter. Hematology. 2013:306-310; 2013